Effect of a Medication Adherence Education Intervention on Clinical Outcomes in Adults with Type 2 Diabetes Mellitus: A Randomized Controlled Trial Study
Abstract
Background: Low adherence to Oral Antidiabetic Drugs (OADs) in adults with Type 2 Diabetes Mellitus (T2DM) leads to complications, death, and increased healthcare costs.
Objective: This study aimed to evaluate the effectiveness of medication adherence education interventions for the clinical outcomes of adults with T2DM.
Materials and methods: Seventy adults with T2DM from an outpatient clinic in the City of Ardabil, Iran, participated in this study. The participants were randomized into an intervention group (n=35) or a non-interventional group (n=35). The intervention group underwent four educational sessions focused on adherence to OADs. Content within classes was influenced by a participant's Stage of Change (SOC) result, which was related to behavior change modeling. Participants in the non-interventional group were placed on a waiting list to receive educational content after the follow- up. Assessments were conducted at baseline, four weeks, and six months.
Results: Significant improvements in Fasting Plasma Glucose (FPG) (P = 0.018) and 2-hour Plasma Glucose (2-hPG) (P < 0.001) levels were found in the intervention group compared to the noninterventional group post-intervention. Additionally, HbA1C was significantly lower at follow-up in the intervention group than in the non-intervention group (P < 0.001). The Homeostasis Model of Insulin Resistance Assessment (HOMA-IR) revealed a significant increase in target cell sensitivity to insulin in the intervention group…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 35 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.